Results from the ELIANA pivotal clinical trial showed the long-term benefit of Kymriah (tisagenlecleucel) in children and young adult patients with relapsed or refractory B-cell acute lymphoblastic leukemia, with a maximum survival follow-up of 5.9 years.
The U.S. Senate didn’t take up the Mikaela Naylon Give Kids a Chance Act after two Senate members—Bernie Sanders (I-VT) and Sen. Markwayne Mullin (R-OK)— voted “Nay,” blocking it.
